Novartis (NVS) Stock Plunges 12% as Del-Desiran Trial Flops in Brutal Week
Novartis (NVS) stock crashed 12% after del-desiran failed Phase III HARBOR trial, the third drug setback this week for the pharmaceutical company.
The post Novartis (NVS) Stock Plunges 12% as Del-Desiran Trial Flops in Brutal Week appeared first on Blockonomi.
Source: Source: Blockonomi